These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 25934691

  • 1. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
    Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C.
    Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
    [Abstract] [Full Text] [Related]

  • 2. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
    Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL.
    Oncotarget; 2015 Aug 21; 6(24):20525-39. PubMed ID: 25971211
    [Abstract] [Full Text] [Related]

  • 3. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
    Kerr C, Szmacinski H, Fisher ML, Nance B, Lakowicz JR, Akbar A, Keillor JW, Lok Wong T, Godoy-Ruiz R, Toth EA, Weber DJ, Eckert RL.
    Oncogene; 2017 May 25; 36(21):2981-2990. PubMed ID: 27941875
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
    Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K.
    Breast Cancer Res; 2012 Jan 06; 14(1):R4. PubMed ID: 22225906
    [Abstract] [Full Text] [Related]

  • 7. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A, Mehta K.
    Drug Resist Updat; 2007 Jan 06; 10(4-5):144-51. PubMed ID: 17662645
    [Abstract] [Full Text] [Related]

  • 8. Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
    Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, Eckert RL.
    Cancer Res; 2016 Dec 15; 76(24):7265-7276. PubMed ID: 27780825
    [Abstract] [Full Text] [Related]

  • 9. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
    Obara Y, Yanagihata Y, Abe T, Dafik L, Ishii K, Nakahata N.
    Cell Signal; 2013 Mar 15; 25(3):589-97. PubMed ID: 23200849
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The complex role of transglutaminase 2 in glioblastoma proliferation.
    Gundemir S, Monteagudo A, Akbar A, Keillor JW, Johnson GVW.
    Neuro Oncol; 2017 Feb 01; 19(2):208-218. PubMed ID: 27591334
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
    Chen X, Adhikary G, Newland JJ, Xu W, Ma E, Naselsky W, Eckert RL.
    Mol Carcinog; 2023 Jan 01; 62(1):90-100. PubMed ID: 35848131
    [Abstract] [Full Text] [Related]

  • 19. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
    Wang X, Yu Z, Zhou Q, Wu X, Chen X, Li J, Zhu Z, Liu B, Su L.
    Oncotarget; 2016 Feb 09; 7(6):7066-79. PubMed ID: 26771235
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.